KainosMed Reorganizes into Four Divisions... "Lee Jae-ho Joins as Vice President and CFO"

[Asia Economy Reporter Hyunseok Yoo] Kainosmed, a company developing central nervous system (CNS) drugs, announced on the 7th that it has recently carried out an organizational restructuring to establish a foundation for long-term growth.

Kainosmed reorganized from its previous structure of an affiliated research institute, new business development department, and management support department into a system of four headquarters: New Drug Development Headquarters, New Business Headquarters, Management Strategy Headquarters, and Management Support Headquarters, thereby strengthening its expertise.

The company appointed Jaehong Lee, an expert in mergers and acquisitions (M&A) and corporate investment, as Chief Financial Officer (CFO) and named him head of the Management Strategy Headquarters. The New Business Headquarters and New Drug Development Headquarters are led by Vice President Gu Lee and Director Jaewook Jung, respectively.

The Parkinson’s disease treatment (KM-819) continues to be overseen by Vice President Jaemoon Lee, who is in charge of clinical development at the U.S. subsidiary Fascinate Therapeutics.

A company official stated, “Through this organizational restructuring, Kainosmed has established a younger and more sustainable system for long-term growth. We will focus on stable growth not only through new drug development projects such as the existing Parkinson’s disease treatment but also through domestic and international M&A and new business ventures.”